Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer
Study Objectives:

Primary objective

* The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously treated with BEP.

Secondary Objectives

* Overall survival
* Progression free survival
* Response rates (RECIST)
* Duration of response
* To investigate the safety of paclitaxel, gemcitabine and cisplatin in patients previously treated with BEP
Testicular Cancer
DRUG: Paclitaxel|DRUG: Cisplatin|DRUG: Gemcitabine
Primary objective · The primary objective of this study is to investigate the combination of cisplatin/gemcitabine/paclitaxel, with respect to complete remission in patients with germ cell tumours previously treated with BEP. · ·, December 2010
Secondary Objectives · Overall survival, 5 years|Secondary Objectives · Progression free survival, 5 years|Secondary Objectives · Response rates (RECIST), 5 years|Secondary Objectives · Duration of response, 5 years|Secondary Objectives · To investigate the safety of paclitaxel, gemcitabine and cisplatin in patients previously treated with BEP, 5 years
not relevant